PL2118128T3 - Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1 - Google Patents

Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1

Info

Publication number
PL2118128T3
PL2118128T3 PL08727588T PL08727588T PL2118128T3 PL 2118128 T3 PL2118128 T3 PL 2118128T3 PL 08727588 T PL08727588 T PL 08727588T PL 08727588 T PL08727588 T PL 08727588T PL 2118128 T3 PL2118128 T3 PL 2118128T3
Authority
PL
Poland
Prior art keywords
lage
eso
fusion proteins
tumor rejection
rejection antigens
Prior art date
Application number
PL08727588T
Other languages
English (en)
Polish (pl)
Inventor
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Clement Rioux
Normand Blais
Remi M Palmantier
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL2118128T3 publication Critical patent/PL2118128T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08727588T 2007-01-15 2008-01-11 Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1 PL2118128T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
US91492507P 2007-04-30 2007-04-30
US91484807P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
EP08727588A EP2118128B1 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
PL2118128T3 true PL2118128T3 (pl) 2013-03-29

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08727588T PL2118128T3 (pl) 2007-01-15 2008-01-11 Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1

Country Status (15)

Country Link
EP (1) EP2118128B1 (https=)
JP (1) JP2010532656A (https=)
KR (1) KR20090122426A (https=)
BR (1) BRPI0806501A2 (https=)
CA (1) CA2674458A1 (https=)
DK (1) DK2118128T3 (https=)
EA (1) EA016818B1 (https=)
ES (1) ES2398492T3 (https=)
HR (1) HRP20130022T1 (https=)
MX (1) MX2009007572A (https=)
PE (1) PE20081687A1 (https=)
PL (1) PL2118128T3 (https=)
SI (1) SI2118128T1 (https=)
TW (1) TW200902049A (https=)
WO (1) WO2008089074A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
CA2755734A1 (en) 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AU2012302778B2 (en) * 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン
BR112017013574A2 (pt) 2014-12-23 2018-03-06 Verdon Daniel conjugados de aminoácido e peptídeo e usos dos mesmos
KR102770425B1 (ko) 2016-02-08 2025-02-18 고쿠리츠다이가쿠호진 미에다이가쿠 면역체크포인트 저해제 저항성 종양에 대한 t세포 수주요법의 전처치약
EP3419962A4 (en) 2016-02-26 2020-03-11 Auckland Uniservices Limited CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD
ES3016535T3 (en) * 2018-11-23 2025-05-09 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
WO2001074855A2 (en) * 2000-03-30 2001-10-11 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
CA2551644C (en) * 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
SG159555A1 (en) * 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
WO2007137986A2 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals Sa Vaccination against cancer
PT2114993E (pt) * 2007-01-15 2012-11-28 Glaxosmithkline Biolog Sa Vacina

Also Published As

Publication number Publication date
EP2118128B1 (en) 2012-11-07
JP2010532656A (ja) 2010-10-14
TW200902049A (en) 2009-01-16
WO2008089074A3 (en) 2008-12-31
PE20081687A1 (es) 2008-12-25
WO2008089074A9 (en) 2012-07-12
WO2008089074A2 (en) 2008-07-24
HRP20130022T1 (hr) 2013-02-28
DK2118128T3 (da) 2013-02-18
CA2674458A1 (en) 2008-07-24
EA200900738A1 (ru) 2010-02-26
SI2118128T1 (sl) 2013-02-28
ES2398492T3 (es) 2013-03-19
EA016818B1 (ru) 2012-07-30
EP2118128A2 (en) 2009-11-18
KR20090122426A (ko) 2009-11-30
MX2009007572A (es) 2009-10-13
BRPI0806501A2 (pt) 2014-04-22

Similar Documents

Publication Publication Date Title
PL2118128T3 (pl) Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1
ZA201002160B (en) Human gm-csf antigen binding proteins
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
ZA201003759B (en) Antibodies against human nkg2d and uses thereof
IL232008A (en) Protein isolate heterodimer alpha-4-in-cell-7-specific antigen-binding and various aspects thereof
IL217121A0 (en) Antimicrobial fusion proteins and uses thereof
IL200373A0 (en) Antibodies against erbb3 and uses thereof
IL200808A0 (en) Soluble il-17ra/rc fusion proteins and related methods
IL202128A0 (en) Immunoglobulin fusion proteins
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
PL2144924T3 (pl) Szczepionka z białkiem fuzyjnym
IL220752A0 (en) Tem8 peptides and vaccines comprising the same
IL200615A0 (en) Monoclonal human tumor-specific antibody
IL203429A0 (en) Immunogenic polypeptides and monoclonal antibodies
EP2797629A4 (en) AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
ZA200901680B (en) Recombinant human interferon-like proteins
EP2303909A4 (en) PEPTIDES EPITOPES DERIVED FROM IQGAP3 AND VACCINES CONTAINING THEM
IL206334A0 (en) Sarp-i fusion proteins and their use
PT2118128E (pt) Proteínas de fusão compreendendo os antigénios de rejeição tumoral ny-eso-1 e lage-1
GB0700759D0 (en) Novel fusion protein
GB0713169D0 (en) Fusion proteins
PL380011A1 (pl) Nowe szkieletowe preparaty białkowe, sposób ich otrzymywania oraz zastosowania
GB0709707D0 (en) Novel fusion protein
GB0506945D0 (en) Human antibodies